Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02211560 · ClinicalTrials.gov registry record · NA
Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment
A NA study, sponsored by Enzymotec.
- Terminated
- Registry status
- NA
- Development phase
- 97
- Enrollment target
NCT02211560: Clinical Trial NA study, sponsored by Enzymotec.
NCT02211560 is a NA study that was terminated before completion, run by Enzymotec. The registered enrollment target is 97 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02211560, a NA study, was terminated before completion, sponsored by Enzymotec.
- TERMINATED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
Interventions
- OTHER Placebo
- OTHER Phosphatidylserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-12-25 |
| Phase | NA |
Why NCT02211560 stopped before completion
NCT02211560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02211560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02211560 about?
NCT02211560 is a clinical study titled "Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment". The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
What is the current status of trial NCT02211560?
This trial is currently terminated. It is a NA study. The enrollment target is 97 participants. The study started on 2014-09. Estimated completion is 2017-12-25.
What interventions are being tested in trial NCT02211560?
The interventions under investigation include: Placebo (OTHER), Phosphatidylserine (OTHER).
Who is sponsoring clinical trial NCT02211560?
This trial is sponsored by Enzymotec, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02211560's enrollment target sits among peer trials
97 923rd of 2000 higher than 1,076 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia